News und Analysen
![Bayer: Diese Gewinnwarnung ist gar nicht das Problem!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Bayer: Diese Gewinnwarnung ist gar nicht das Problem!
Der Leverkusener Chemie- und Pharmagigant Bayer (WKN: BAY001) legte heute früh seine aktuellen Quartalszahlen vor. Demnach wurde in Q2 ein Umsatz in Höhe von 10,05 Milliarden Euro bei einem EBIT von
![Bayer: Diese Gewinnwarnung ist gar nicht das Problem!](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Bayer: Diese Gewinnwarnung ist gar nicht das Problem!
Der Leverkusener Chemie- und Pharmagigant Bayer (WKN: BAY001) legte heute früh seine aktuellen Quartalszahlen vor. Demnach wurde in Q2 ein Umsatz in Höhe von 10,05 Milliarden Euro bei einem EBIT von
![NanoString Extends Leadership in Spatial Genomics with Launch of GeoMx DSP Read-Out for Next Generation Sequencers](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
NanoString Extends Leadership in Spatial Genomics with Launch of GeoMx DSP Read-Out for Next Generation Sequencers
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the first GeoMx®
![Trevena vor FDA-Entscheidung: +331% nach NBC-Empfehlung!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Trevena vor FDA-Entscheidung: +331% nach NBC-Empfehlung!
Woche der Wahrheit für Trevena (WKN: A1XDSL): Die US-Gesundheitsbehörde wird bis Freitag über die Zulassung des Schmerzmittels Oliceridine entscheiden.
Bis 2,89 USD geht es für die Trevena-Aktie
![Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food
![Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based
![Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based
![Quidel Reports Second Quarter 2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Quidel Reports Second Quarter 2020 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
![First EOSedgeTM installation in the United States](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
First EOSedgeTM installation in the United States
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces
![Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a data licensing agreement with the National Institutes of Health (NIH). Under the terms of the agreement
![Savara to Report Second Quarter 2020 Financial Results and Provide Business Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6
![Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
![Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize
![Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets
![Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical
![CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
![Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market
![Premier Inc. Technology Predicts Number of COVID-19 Cases in U.S. Hospitals in Near Real Time](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier Inc. Technology Predicts Number of COVID-19 Cases in U.S. Hospitals in Near Real Time
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given
![Humana and Heal Announce National Partnership to Transform Home Care for Medicare Advantage Members and Others](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Humana and Heal Announce National Partnership to Transform Home Care for Medicare Advantage Members and Others
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, and Heal, a market leader in transforming healthcare through in-home, comprehensive primary care, today
![LivaNova Reports Second Quarter 2020 Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
LivaNova Reports Second Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.
For the second quarter of 2020, worldwide sales
![Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
![Premier, Inc. to Report Fiscal 2020 Fourth-Quarter and Full-Year Results and Host Conference Call on August 25, 2020](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Premier, Inc. to Report Fiscal 2020 Fourth-Quarter and Full-Year Results and Host Conference Call on August 25, 2020
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2020 fourth quarter and full year on Tuesday, August 25, 2020, at approximately 6:30 a.m. EDT. The
![Dexcom Reports Second Quarter 2020 Financial Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Dexcom Reports Second Quarter 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.
Second Quarter 2020 Financial Highlights:
-
Revenue grew 34% versus the same
![Dexcom Reports Second Quarter 2020 Financial Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Dexcom Reports Second Quarter 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.
Second Quarter 2020 Financial Highlights:
-
Revenue grew 34% versus the same